secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001576885-23-000068
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen posts updated corporate presentation with plasma biomarker data from Phase 1 INTERCEPT-AD trial
--------------------------------------------------------------------------------

- Updated corporate presentation posted to investor website on December 4, 2023.
- Includes plasma biomarker data from Phase 1 INTERCEPT-AD trial.
- Presentation to be used in upcoming investor conferences and communications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000068/0001576885-23-000068-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000157688523000068/abos-20231204.htm
  HTML page:      https://secwatch.observer/filing/0001576885-23-000068

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer